Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
An FDA advisory panel voted late last week to keep the black-box warning on the smoking cessation drug varenicline (Chantix), Reuters reports. The warning alerts providers and patients to the potential for adverse neuropsychiatric events, including suicidal behavior.
The manufacturer requested the label change after new observational data and meta-analyses suggested no increase in neuropsychiatric risk. The FDA advisers, however, cautioned that the new data do not include all possible psychological effects. They said they would reconsider the warning after seeing results from the manufacturer's current 8000-patient study, which is comparing neuropsychiatric outcomes in patients on varenicline, two other cessation treatments, and placebo. The results are expected in the second half of 2015.
Comment
LINK(S):
Reuters story (Free)
Background: Physician's First Watch recent coverage of move to remove boxed warning (Free)